

S/N 09/590002

#14
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lawrence L. Kunz et al.

Examiner: Samuel Barts

Serial No.: 09/590002

Group Art Unit: 1621

Filed: June 08, 2000

Docket: 295.007US

Title: THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. § 1.97(c)(2), Applicant has included the fee of \$180.00 set forth in 37 C.F.R. §1.17(p). Please charge any additional fees or credit any overpayment to Account No. 19-0743. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
LAWRENCE L. KUNZ ET AL.
By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
612-373-6959

Date February 28, 2003

By [Signature]
Janet E. Embretson
Reg. No. 39,665

03/04/2003 CCHAU1 00000170 09590002

01 FC:1806

180.00 0P

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 28 day of February, 2003.

Name

[Signature]

Signature

[Signature]